| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-(Chloromethyl)-3,4-dimethoxypyridine hydrochloride does not have a defined pharmacological target as it is a synthetic intermediate. The compound is used as a building block in organic synthesis and drug development. The pyridine ring with methoxy and chloromethyl substituents provides a versatile scaffold for constructing more complex molecules for pharmaceutical research. The compound serves as a precursor for the synthesis of various bioactive compounds.
|
|---|---|
| ln Vitro |
No direct in vitro pharmacological activity data are available for 2-(chloromethyl)-3,4-dimethoxypyridine hydrochloride as it is a synthetic intermediate. The compound is used in medicinal chemistry as a building block for synthesizing libraries of pyridine-based compounds that are subsequently screened for biological activity. Its activity is assessed in terms of synthetic utility and reactivity rather than direct biological activity.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 2-(chloromethyl)-3,4-dimethoxypyridine hydrochloride as it is not a therapeutic agent. The compound is used in chemical synthesis and drug development. It is not administered directly to animals. Its derivatives and the compounds synthesized from it may be evaluated in animal models depending on the therapeutic area.
|
| Enzyme Assay |
For non-cellular assays, 2-(chloromethyl)-3,4-dimethoxypyridine hydrochloride is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a substrate in various organic reactions including nucleophilic substitution and coupling reactions. Typical protocols involve dissolving the compound in appropriate solvents and analyzing reaction products by chromatographic methods. Purity is typically ≥98%.
|
| Cell Assay |
2-(Chloromethyl)-3,4-dimethoxypyridine hydrochloride is not typically used in direct cell-based assays as it is a chemical intermediate. The compound is used as a building block for synthesizing biologically active molecules that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken. The compound should be stored in a cool, dry place at room temperature (recommended <15°C).
|
| Animal Protocol |
2-(Chloromethyl)-3,4-dimethoxypyridine hydrochloride is not used in animal studies as it is a chemical reagent. The compound is handled in chemistry laboratories for organic synthesis applications. Storage: keep in a cool, dark place at room temperature (recommended <15°C). The compound should be stored in a tightly sealed container. Standard handling procedures for chlorinated compounds and pyridine derivatives should be followed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for 2-(chloromethyl)-3,4-dimethoxypyridine hydrochloride as it is a synthetic intermediate. The compound has a molecular weight of 224.08-224.84 and molecular formula C8H11Cl2NO2. It is a solid at 20°C. Storage: room temperature in a cool and dark place (<15°C). The compound has an EINECS number of 416-440-5 and MDL number MFCD02181083. Purity: typically ≥98%.
|
| Toxicity/Toxicokinetics |
2-(Chloromethyl)-3,4-dimethoxypyridine hydrochloride is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Chlorinated compounds should be handled with care. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
2-(Chloromethyl)-3,4-dimethoxypyridine hydrochloride (CAS 72830-09-2) is a versatile compound with significant implications in chemical synthesis and drug development. It may be used as a precursor for the preparation of [(2-pyridyl)-2-ethyl]-[3,4-dimethoxy-(2-pyridylmethyl)]-N-methylamine. No clinical trials or therapeutic approvals exist; the product is exclusively for research purposes.
|
| Molecular Formula |
C8H11CL2NO2
|
|---|---|
| Molecular Weight |
224.08
|
| Exact Mass |
223.016
|
| CAS # |
72830-09-2
|
| PubChem CID |
16216928
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
293.9ºC at 760 mmHg
|
| Melting Point |
155 °C (dec.)(lit.)
|
| Flash Point |
131.6ºC
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
134
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC([H])([H])C1C(=C(C([H])=C([H])N=1)OC([H])([H])[H])OC([H])([H])[H].Cl[H]
|
| InChi Key |
YYRIKJFWBIEEDH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10ClNO2.ClH/c1-11-7-3-4-10-6(5-9)8(7)12-2;/h3-4H,5H2,1-2H3;1H
|
| Chemical Name |
2-(chloromethyl)-3,4-dimethoxypyridine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~13.3 mg/mL (~59.5 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.33 mg/mL (5.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (13.3 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.33 mg/mL (5.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (13.3 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4627 mL | 22.3135 mL | 44.6269 mL | |
| 5 mM | 0.8925 mL | 4.4627 mL | 8.9254 mL | |
| 10 mM | 0.4463 mL | 2.2313 mL | 4.4627 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
